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Lanosterol induces mitochondrial uncoupling and
protects dopaminergic neurons from cell death in
a model for Parkinson’s disease
L Lim*,1, V Jackson-Lewis2, LC Wong3, GH Shui4, AXH Goh4, S Kesavapany4, AM Jenner4,7, M Fivaz3,5, S Przedborski2
and MR Wenk*,1,4,6
Parkinson’s disease (PD) is a neurodegenerative disorder marked by the selective degeneration of dopaminergic neurons in the
nigrostriatal pathway. Several lines of evidence indicate that mitochondrial dysfunction contributes to its etiology. Other studies
have suggested that alterations in sterol homeostasis correlate with increased risk for PD. Whether these observations are
functionally related is, however, unknown. In this study, we used a toxin-induced mouse model of PD and measured levels of
nine sterol intermediates. We found that lanosterol is significantly (B50%) and specifically reduced in the nigrostriatal regions of
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice, indicative of altered lanosterol metabolism during PD pathogenesis.
Remarkably, exogenous addition of lanosterol rescued dopaminergic neurons from 1-methyl-4-phenylpyridinium (MPPþ )-
induced cell death in culture. Furthermore, we observed a marked redistribution of lanosterol synthase from the endoplasmic
reticulum to mitochondria in dopaminergic neurons exposed to MPPþ , suggesting that lanosterol might exert its survival effect
by regulating mitochondrial function. Consistent with this model, we find that lanosterol induces mild depolarization of
mitochondria and promotes autophagy. Collectively, our results highlight a novel sterol-based neuroprotective mechanism with
direct relevance to PD.
Cell Death and Differentiation (2012) 19, 416–427; doi:10.1038/cdd.2011.105; published online 5 August 2011
Parkinson’s disease (PD) is a movement disorder marked by
the selective degeneration of dopaminergic neurons in the
nigrostriatal pathway. About 5–10% of PD are genetically
linked with mutations in genes such as leucine-rich repeat
kinase 2 (LRRK2), alpha-synuclein, PTEN-induced putative
kinase 1 (PINK1), Parkin and DJ-1.1 These genetic PD cases,
while rare, have provided insights into mechanisms of PD
pathogenesis and many of which point toward mitochondrial
dysfunction.1–3 For example, PINK1, Parkin and DJ-1 control
clearance of mitochondria by mitophagy in response to
cellular stress.3 Mitochondrial defects are also seen in
idiopathic PD, whereby the catalytic activity of brain mito-
chondrial complex I is compromised.4 Finally, environmental
toxins that affect complex I, such as 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP),5 can also induce
Parkinsonism. The active metabolite of MPTP, 1-methyl-4-
phenylpyridinium (MPPþ ), selectively enters dopaminergic
neurons via the dopamine transporter, inhibits mitochondrial
complex I and eventually induces clinical symptoms
reminiscent of PD.
As MPTP/MPPþ toxicity emulate PD symptoms, it has
been widely used in animal and cellular models to study
neuronal cell death and to screen for neuroprotective agents.
Of the neuroprotective metabolites identified, many are found
in mitochondria, including L-carnitine, creatine and coenzyme
Q (CoQ)-10.6 Although their precise protective mechanisms
are still poorly understood, some evidence suggests that they
act as mitochondrial uncouplers.7 Consistent with this model,
uncoupling proteins (UCPs) are protective in the MPTP model
of PD,8,9 and their expression is downregulated in DJ-1 knock-
out mice.10 Neuronal cell death induced by glutamate toxicity
can also be rescued by mitochondrial uncouplers.11
More recently, misregulation of sterol metabolism has
also been implicated in PD. In clinical studies, elevation of
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low-density lipoprotein cholesterol (LDL-C) in serum corre-
lates with higher prevalence of PD,12 whereas higher serum
levels of total cholesterol are associated with a decreased risk
of PD.13 Biochemical studies showed that alpha-synuclein,
the major component of Lewy bodies found in PD brains,
binds to cholesterol with high affinity,14 and its aggregation is
accelerated in presence of oxidized cholesterol.15 In a
separate line of investigation, oxidative stress has been
shown to increase levels of lanosterol, a cholesterol pre-
cursor, in mitochondria and several other intracellular
compartments of macrophages, suggesting that this sterol
metabolite may be part of a global cellular response to
stress.16 Yet, how sterol metabolism is altered in the brains of
PD patients, or which sterol metabolites, if any, have an
impact on the survival of dopaminergic neurons is unknown.
Our study investigated the role of sterol metabolism in the
MPTP/MPPþ model of PD. Our results provide evidence for
the specific role of lanosterol as a neuroprotective agent in
dopaminergic neurons. We also show that lanosterol induces
mild uncoupling of mitochondria and promotes autophagy,
two events that have been previously linked to neuroprotec-
tion in various models of PD. To our knowledge, our work
provides the first link between sterol metabolism and
mitochondrial function, and identifies lanosterol as a potential
therapeutic agent for PD.
Results
Lanosterol levels are decreased in the striatum and
ventral midbrain of MPTP-injected mice. To determine if
sterol metabolism is altered in a rodent model of PD, we
measured levels of sterol metabolites in the striatum and
ventral midbrain of control and MPTP-treated mice by gas
chromatography-mass spectrometry (GC–MS). This acute
MPTP injection regime results in about 35% loss of
dopaminergic neurons after 48 h.17 Of the nine metabolites
analyzed, we found that lanosterol, the first cyclic sterol, was
reduced byB50% in affected areas (Figure 1). Owing to the
specific and highly significant reduction in the levels of
lanosterol in the affected areas of MPTP-treated animals, we
reasoned that lanosterol might be important for dopaminergic
neuronal survival.
Lanosterol protects dopaminergic neurons from MPPþ
-induced cell death. We asked whether exogenous addition
of lanosterol protects dopaminergic neurons against MPPþ -
induced cell death. Primary postnatal neuron cultures from the
ventral midbrain were treated with MPPþ , and the survival of
dopaminergic neurons was determined in the absence or
presence of exogenously added lanosterol. In all, 48% of
dopaminergic neurons survived on treatment with MPPþ
under these culture conditions (Figures 2a and c).
Co-incubation of MPPþ with phosphatidylcholine (PC,
vehicle control) or cholesterol did not improve survival of
dopaminergic neurons (Figures 2b and c). In contrast, co-
treatment of the cultures with MPPþ and lanosterol increased
survival of dopaminergic neurons to 76% (Figures 2b and c).
Thus, lanosterol, but not cholesterol or PC, rescues
dopaminergic neurons from MPPþ -induced cell death.
To determine if addition of lanosterol in culture affects other
sterol intermediates, we analyzed an array of metabolites
(squalene, lanosterol, lathosterol, 7-dehydrocholesterol,
desmosterol, cholesterol, 7-b hydroxycholesterol, 7-keto-
cholesterol and 24-hydroxycholesterol) in extracts from
ventral midbrain cultures by GC–MS. In cells treated with
lanosterol, we observed a 12-fold increase in lanosterol
levels relative to control (no treatment, Figures 2d and e) and
no detectable effect on other sterol metabolites tested
(Figure 2e), suggesting that cells have a high capacity to
accumulate lanosterol, consistent with previous findings in
macrophages.16 This is not the case for cholesterol, as we did
not detect any changes in cholesterol levels on exogenous
addition of cholesterol, perhaps because neuronal cholesterol
homeostasis is tightly regulated.18 In addition to the metabo-
lites indicated above, we also tested the impact of lanosterol
and cholesterol addition on levels of ubiquinones, isoprenoid-
derived electron carriers in mitochondria, and found no
significant differences (Figures 3a and b).
In these experiments, postnatal dopaminergic neurons
were grown in direct contact with a glia feeder. It is therefore
possible that neuroprotection is indirectly mediated by a
modification of astrocyte physiology. To address whether
lanosterol addition leads to a specific increase in lanosterol
concentration in neurons, we repeated these experiments
using hippocampal neurons cultured according to Banker’s
method,19 which allows physical separation of neurons and
astrocytes. We found that lanosterol levels increased in both
neurons and astrocytes to a similar extent on treatment with
exogenous lanosterol (data not shown). Although we cannot
rule out the possible contribution of astrocytes in lanosterol-
mediated neuroprotection, our results indicate that lanosterol
levels are significantly elevated in neurons, arguing for a direct
role of lanosterol in promoting survival of dopaminergic
neurons.
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Figure 1 Lanosterol is the only sterol specifically depleted in affected brain
areas of mice treated with MPTP. C576B6 mice were treated with the acute
schedule of MPTP injections. At 48 h after the last dose of MPTP, the ventral
midbrain and striatum were dissected, and lipids were extracted for analysis of sterol
intermediates by GC–MS. Fold changes are plotted on the y axis, which represent
the average levels from MPTP-treated animals (n¼ 4) normalized to average levels
from saline-treated (control) animals (n¼ 6) for each metabolite. Error bars
represent S.E.M. In both brain regions, the levels of lanosterol are reduced
significantly in MPTP-treated animals. ***Po0.001
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To explore the mechanisms underlying lanosterol-mediated
neuroprotection, we next investigated the effects of MPPþ
and lanosterol on various signaling pathways previously
implicated in cellular metabolism and neurodegeneration.
First, we examined the expression level of sterol response
element-binding protein (SREBP2, Figure 4a), a transcription
factor reported to exacerbate neuronal degeneration.20
We found that MPPþ induced a modest increase in
SREBP2 levels, which was not rescued by lanosterol
addition (Figure 4a, top panel). We also checked for levels
of cdk5 activator protein with 35 kDa (p35), the activator of
cyclin-dependent kinase 5 (cdk5), because the genetic
ablation of p35/cdk5 confers neuroprotection in the MPTP
model.21 Although we observed a decrease in p35 levels in
MPPþ -treated cells, addition of lanosterol did not restore
p35 expression to control levels (Figure 4a, second panel
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Figure 2 Lanosterol rescues dopaminergic neurons in MPPþ -treated ventral midbrain cultures. Fluorescence images of primary ventral midbrain cultures (DIV7) stained
with anti-TH, a marker for dopaminergic neurons. (a) Control cells (no treatment) and cells treated with 10 mM MPPþ ; (b) co-treated cells for 24 h with 10mM MPPþ and
5mM of phosphatidylcholine (PC, left panel), lanosterol (middle panel) or cholesterol (right panel). Scale bars in (a) and (b) represent 200mm. (c) Plot of fold changes of each
treatment relative to control. y axis shows the average percentage of THþ neurons from each treatment condition divided by the average percentage of THþ neurons in
control. Error bars represent S.E.M. from four to five independent experiments. ***Po0.001 between lanosterol/MPPþ and MPPþ . (d) GC–MS profiles of lanosterol
(m/z 393, light grey) and the internal standard (deuterated b-sitosterol, m/z 493, black) in ventral midbrain cultures incubated for 24 h with various lipid treatments. (e) Cellular
levels of sterol intermediates following various treatments normalized to control (no treatment). Fold changes plotted in y axis represent the levels of each metabolite in each
treatment condition normalized to control. Error bars represent S.E.M. from three independent experiments. ***Po0.001 between lanosterol treatment and control
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from top). Consistent with previous findings implicating
glycogen synthase kinase 3 beta (Gsk-3b) (Ser9) phosphor-
ylation in PD pathogenesis,22 we found increased phospho-
Gsk-3b in MPPþ -treated cells. However, this increase was
not affected by the addition of lanosterol (Figure 4a, third
panel from top).
Finally, we examined the levels of lanosterol synthase
(LSS), the enzyme that catalyzes cyclization of oxidosqua-
lene, the rate limiting step in lanosterol synthesis.23 The levels
of LSS did not markedly change on MPPþ addition
(Figure 4a, fourth panel from top). Interestingly, however,
we observed a different localization pattern of LSS in MPPþ
-treated dopaminergic neurons. LSS immunostaining
appeared much more punctate after MPPþ treatment
(Figure 4b), suggesting drug-induced redistribution of LSS
to a different intracellular compartment. We thus proceeded to
examine the subcellular localization of LSS in control and
MPPþ -treated dopaminergic neurons.
Redistribution of LSS in dopaminergic neurons on
MPPþ insult. LSS is a membrane-associated enzyme,
which is targeted to the cytoplasmic leaflet of the
endoplasmic reticulum (ER).24 Biochemical analysis of
purified fractions from mouse liver showed that the bulk of
LSS is indeed associated with the microsomal/ER fractions
and that minor amounts are found in purified mitochondria
(Figure 4c).
Consistent with our biochemical fractionation data, we
found that LSS colocalized with an ER marker (ER retention
sequence (lys-asp-glu-leu) (KDEL)) in both dopaminergic and
non-dopaminergic neurons (Figure 5a). Extensive overlap
between LSS and the ER marker was observed for both
dopaminergic and non-dopaminergic neurons (R2¼ 0.83±
0.01 and 0.84±0.01, respectively). Less overlap was found
between LSS and translocase of outer mitochondrial mem-
brane 20 (TOMM20) (a mitochondrial marker) for both
dopaminergic and non-dopaminergic neurons (R2¼ 0.70±
0.02 and 0.69±0.02, respectively, Figure 5a, second panel
from the top). This pattern changed noticeably in dopaminer-
gic neurons treated with MPPþ . The colocalization of LSS
with TOMM20 was markedly increased (R2¼ 0.856±0.01,
Figure 5a, bottom last panel), with concomitant reduction in
the overlap of LSS with KDEL (R2¼ 0.69±0.02, Figure 5a,
second panel from the bottom). Translocation of LSS from the
ER to mitochondria was also observed in dopaminergic
neurons co-treated with MPPþ and lanosterol (Figure 5b).
MPPþ did not, however, affect LSS localization in non-
dopaminergic neurons (Figure 5b), consistent with the inability
of these cells to take up MPPþ . These data indicate that a
significant fraction of LSS redistributes from the ER to
mitochondria in dopaminergic neurons exposed to MPPþ ,
suggesting that LSS (and its product lanosterol) may have a
role in regulating mitochondrial function.
Lanosterol uncouples mitochondria in dopaminergic
neurons. An important aspect of mitochondrial physiology
can be assessed by measuring the mitochondrial membrane
potential (Dc), which is the electrical and chemical gradient
that drives protons across the inner membrane during
electron transport and oxidative phosphorylation. This
process is never completely ‘coupled’, allowing a fraction of
electrons and protons to be transported without concurrent
production of adenosine triphosphate (ATP). We first
examined the impact of lanosterol on Dc in hippocampal
neurons using the ratiometric voltage-sensitive fluorescent
dye, 5,50,6,60-tetrachloro-1,10,3,30-tetraethylbenzimidazolocarbo-
cyanine iodide (JC-1). Using time-lapse, multi-positioning
imaging to capture about 3–4 fields in 30-s intervals, we
measured changes of Dc on lipids addition by the ratiometric
analysis of JC-1 red to green emission. As expected,
treatment of neurons with 200 nM m-chlorophenylhydrazone
(CCCP), a known uncoupler of oxidative phosphorylation,
induced an immediate and sharp reduction of the
mitochondrial membrane potential (B25% within 30 s;
Figure 6a). Under these same experimental conditions,
exogenous addition of lanosterol reduced the membrane
potential byB20% over 15 min, whereas PC and cholesterol
had no significant effect (Figure 6b).
We repeated these experiments in ventral midbrain cultures
(Figures 6c and d). As these cultures were grown at a lower
density than the hippocampal cultures, we needed to capture
10–15 fields in time-lapse multi-positioning imaging at lower
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magnification to gain enough statistical power. As a conse-
quence, this limited time intervals to 2 min. We observed a
B20% of reduction in membrane potential on lanosterol
addition (Figures 6c and d), consistent with the results
obtained in hippocampal neurons.
As MPPþ uptake depends on ATP levels,25 it is possible
that the addition of lanosterol causes mitochondrial depolar-
ization, and subsequently ATP depletion. This would, in turn,
inhibit MPPþ uptake in the mitochondria. To determine if
lanosterol alters ATP levels, we measured levels of ATP in
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and MPPþ treatment. White boxes show dopaminergic neurons as determined by THþ staining. Right panels show pixel intensity correlation plots of LSS with either KDEL
or TOMM20 in dopaminergic neurons. Scale bar represents 10 mm. (b) Average R2 values (a measure of colocalization) of two classes of neurons in control and MPPþ
-treated conditions. In control, R2 values from co-staining of KDEL-LSS, n¼ 26 and n¼ 27, TOMM20-LSS, n¼ 20 and n¼ 21, were assessed for dopaminergic and non-
dopaminergic neurons respectively. In MPPþ -treated cells, R2 values from co-staining of KDEL-LSS, n¼ 20 and n¼ 20, for TOMM20-LSS, n¼ 18 and n¼ 17, were
assessed for dopaminergic and non-dopaminergic neurons respectively. In MPPþ /lanosterol co-treated cells, R2 values from co-staining of KDEL-LSS, n¼ 18 and n¼ 23,
for TOMM20-LSS, n¼ 19 and n¼ 18, were assessed for dopaminergic and non-dopaminergic neurons respectively. ****Po0.00001
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neurons treated with PC, cholesterol or lanosterol. We did not
see any significant changes in the levels of ATP across all
treatment conditions (Supplementary Figure S1), indicating
that lanosterol is unlikely to inhibit MPPþ uptake. Thus, one
mechanism by which lanosterol could mediate neuroprotec-
tion is through the uncoupling of mitochondria.
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Lanosterol increases autophagy in dopaminergic
neurons. Previous studies have shown that the loss of
mitochondrial membrane potential can initiate the autophagic
degradation of damaged mitochondria.26,27 Gene linked to
familial forms of PD, such as PINK1 and Parkin, are thought
to regulate this process, and PD-associated Parkin mutations
cause a decrease in mitophagy in mammalian cell lines.28
We thus asked if lanosterol mediates autophagosome
formation in dopaminergic neurons. Using microtubule-
associated protein light chain 3 (LC3) as a marker for
autophagy, we quantified both the size and number of
autophagic vacuoles (AVs) in primary ventral midbrain
neurons on MPPþ /lanosterol treatment. Similar to other
studies,29 we found that addition of MPPþ in primary
dopaminergic neurons increased the number of AVs by
about 2.5-fold (Figure 7). There is also about a 75% increase
in the average size of AVs with MPPþ treatment.
Remarkably, when neurons were exposed to lanosterol
alone, we observed a similar increase in AV size and
number. Co-treatment of MPPþ and lanosterol led to an
additive effect on autophagy, with significant increases in
both the number and size of AVs, compared with MPPþ or
lanosterol alone (Figure 7).
Next, we addressed whether lanosterol has a specific effect
on axonal mitophagy. In PD, axons of dopaminergic neurons
progressively degenerate and ‘die back’, in a process that
may be accelerated by mitochondrial dysfunction and involve
mitophagy. For this, we grew hippocampal neurons in
microfluidic chambers to segregate axons from neuronal cell
bodies and dendrites.30 Mitochondria were visualized by
expression of the fluorescent reporter MitoRed and neurons
were immunostained for endogenous LC3. We found a small
but significant increase in colocalization of MitoRed with LC3
(Figure 8) on lanosterol treatment, suggesting an increase in
axonal mitophagy. Taken together, these results suggest that
the protective effects of lanosterol are mediated by mitochon-
dria uncoupling, and subsequent clearance of damaged
mitochondria.
Discussion
The etiology of PD implicates several factors, including
mitochondrial dysfunction and misregulation of sterol meta-
bolism. Evidence implicating impaired mitochondrial function
in PD is substantial. This evidence is based on (1) the
identification of rare PD-associated mutations in genes that
affect mitochondrial function such as the putative kinase,
PINK1 (PARK6), the E3 ligase Parkin (PARK2) and DJ-1
(PARK7); (2) similarities between PD and clinical symptoms
that arise on exposure to the neurotoxin MPTP, a complex I
inhibitor; and (3) a significant decrease in complex I/II activity
in the platelets of patients with PD.31
On the other hand, evidence for a role of aberrant sterol
metabolism in PD is rather controversial. For example, lower
levels of serum LDL-C are considered a risk factor for PD,12,32
but it is unclear how serum LDL-C relates to levels of
cholesterol in the brain. Statins, which lower serum cholester-
ol levels by inhibiting 3-hydroxy-3-methyl-glutaryl-coenzyme
A reductase, have been used to treat PD, but there are many
unresolved questions regarding their benefits (see review in
Becker and Meier33).
In this study, we measured a selection of sterol metabolites
in the ventral midbrain and striatum of MPTP-treated mice,
two brain regions characterized by cell death and/or axonal
loss in both the MPTP model as well as in PD. Our results
show a highly selective reduction of lanosterol levels in these
affected areas (Figure 1) and point to an alteration of
lanosterol metabolism in MPTP-treated mice. We cannot
rule out the possibility that lanosterol is oxidized or metabo-
lized to di-hydrolanosterol or other products in MPTP-treated
animals because we are unable to measure these oxidized
metabolites.
Consistent with a role of lanosterol in PD pathogenesis,
we observed an improved survival of MPPþ -treated dopa-
minergic neurons on exogenous addition of lanosterol
(Figure 2). We also demonstrated that LSS relocalized from
the ER to mitochondria in dopaminergic neurons on MPPþ
treatment (Figures 4b and 5), suggesting an increase in
lanosterol synthesis in mitochondria. Interestingly, recent
lipidomic analysis of macrophages during stimulation with
Lipid A (a condition that leads to oxidative bursts) showed
a pronounced increase in lanosterol levels in several
intracellular compartments, including mitochondria,16 impli-
cating that modulation of lanosterol metabolism may be part of
a global cellular response to stress. If upregulation of
lanosterol synthesis is part of a cellular defense mechanism,
it is not clear why lanosterol levels drop in response to
MPTP treatment. In this regard, it is interesting to note that
two recent papers reported lowered lanosterol levels in the
serum of patients with Alzheimer’s disease,34 and in
fibroblasts challenged by virus infection.35 One possible
explanation for these seemingly contradicting results is that
distinct types of stress differentially impact lanosterol meta-
bolism. Perhaps, in some cases, the substantial decrease in
lanosterol levels cannot be compensated by upregulation of
lanosterol synthesis as part of the cell’s protective response.
Alternatively, we cannot exclude the possibility that transloca-
tion of LSS to mitochondria in response to MPPþ is an
epiphenomenon, which is not indicative of a cellular response
to stress.
Our results, however, show that exogenous addition of
lanosterol leads to mild uncoupling of mitochondria in
dopaminergic and glutamatergic neurons, with no detectable
impact on ATP levels (Figure 6 and Supplementary Figure
Figure 6 Lanosterol induces uncoupling of the mitochondria in dopaminergic neurons. Live imaging of JC-1 loaded neuronal cultures. (a) Control plot showing changes in
JC-1 red to green ratio,Df/f0, versus time in hippocampal neurons treated with CCCP, a known uncoupler, n¼ 20. (b) Plot ofDf/f0 versus time in hippocampal neurons treated
with different lipids, n460 for each condition from three independent experiments. (c) Images of control and lanosterol-treated ventral midbrain cultures at the start of the
experiment (time¼ 0 min, left panels) and the end of the experiment (time¼ 40 min, middle panels). Right panels represent posteriori staining of TH for identification of
dopaminergic neurons. White boxes represent magnified THþ neurons. Scale bar represents 100mm in main figure and 10mm in magnified box. (d) Plot ofDf/f0 versus time
for dopaminergic neurons, n410 for each condition from three independent experiments. In both types of cultures, lanosterol induces about 20% decrease in mitochondrial
membrane potential
Lanosterol protects dopaminergic neurons
L Lim et al
423
Cell Death and Differentiation
S1). The mitochondria uncoupling and protective effects of
lanosterol are strikingly similar to those observed with low
dose of the uncoupler, FCCP, which improves cellular survival
in ischemic preconditioning but has no significant impact on
ATP levels.36 In the context of PD, the mitochondrial
uncoupling effect of lanosterol has important implications.
For example, Parkin is recruited to mitochondria via PINK1 on
membrane depolarization,26 and regulates the clearance of
damaged mitochondria by mitophagy in mammalian cell
lines.37 In addition, the translocation of Parkin to mitochondria
has etiological significance, as a number of disease-
associated Parkin mutant proteins fail to translocate.27,38
Together, these data point to a role of mitochondrial
uncoupling and autophagy in PD pathogenesis. In line with
this model, our results reveal that lanosterol induces
mitochondrial uncoupling (Figure 6) and promotes autophagy
(Figures 7 and 8).
Although mitochondrial uncoupling has been shown to be
neuroprotective in various models, including MPTP-induced
neurodegeneration,7–9 the mechanisms involved are still
unclear. Some studies have shown that uncoupling reduces
superoxide species, offering an explanation for improved
TH
LC
3
AV
 id
en
tif
ie
d
control lanosterol MPP+ Lanosterol & MPP+
0
10
20
30
40
50
60
70
number of AV
avg size of AV (pixel area)
***
***
MPP+
PC
-
Lanosterol
Cholesterol
+ +
+ ++ +
----
---
-
-
-- -+--+-
+- ---+--
0
10
20
30
40
50
60
70
N
um
be
r o
f A
V/
 c
el
l 
AV average pixel area/cell
***
a
b
Figure 7 Lanosterol and MPPþ increase the number of AVs in dopaminergic neurons. (a) Confocal images of ventral midbrain neurons stained with TH (top panels), LC3
(middle panels) and AV quantification (ImageJ software output, bottom panels) with various treatment conditions indicated on the top. Scale bar represents 10mm.
(b) Graphical plot showing the average number of AV identified per THþ cells and the average size of AV in pixel area during treatment with various lipids and MPPþ
co-treatment. For each condition, n440 THþ cells from three independent experiments. Error bars represent S.E.M. ***Po0.001
Lanosterol protects dopaminergic neurons
L Lim et al
424
Cell Death and Differentiation
neuronal survival in the MPTP model, because oxidative
stress is thought to be the primary cause of cell death.8,9 In
other studies, transient mitochondrial uncoupling is neuropro-
tective in glutamate-induced neurotoxicity, as it prevents
uptake of calcium from the cytosol to mitochondria.11 Finally, a
recent study showed that DJ-1, a gene involved in early onset
PD, regulates the expression of two UCPs (UCP4 and UCP5)
and controls oxidative stress in mitochondria of dopaminergic
neurons in the substantia nigra.10 Although these studies
cited above have identified different modulators by which a
cell/neuron alters mitochondrial membrane potential, they are
in good agreement with our findings, whereby uncoupling
mechanism proves to be a central regulator of cellular
response to stress.
In conclusion, we report that in addition to its role as a
precursor for cholesterol biosynthesis, lanosterol acts as a
survival factor for dopaminergic neurons. Furthermore, our
findings point to an unexpected role of this sterol metabolite in
regulating mitochondrial function and autophagy, and bring
sterol metabolism to the forefront of neurobiological disease.
Materials and Methods
PD animal model: MPTP injections. All procedures performed in rodents
were in accordance with IACUC guidelines. MPTP injections were performed
according to previously published methods, following the acute schedule.17 Briefly,
C57B6 mice were given four i.p. doses of either 18 mg/kg of MPTP (Sigma-Aldrich,
St. Louis, MO, USA) or saline (control) every 2 h. Mice were decapitated 48 h after
the last dose, and the ventral midbrain and striatum were dissected and snap-frozen
for subsequent lipid extraction and GC–MS analysis. Previously published data
using the same protocol showed that at this timepoint, about 35% of dopaminergic
neurons have degenerated.17
Lipid standards and liposomes. Lanosterol, cholesterol, 1,2-dimyristoyl-
sn-glycero-3-phosphocholine (DMPC or PC) and desmosterol-d6 (all of highest
purity, 499%) were purchased from Avanti Polar Lipids (Alabaster, AL, USA).
Oxysterol standards a-cholestane, 7a-hydroxycholesterol, 7b-hydroxycholesterol,
7-dehydrocholesterol, 25-hydroxycholesterol and 7-ketocholesterol were
obtained from Sigma (St. Louis, MO, USA). 7a-Hydroxycholesterol-d7,
7b-hydroxycholesterol-d7, b-sitosterol-d7, campesterol-d3, lathosterol-d4 and
7-ketocholesterol-d7 were purchased from CDN Isotopes (Quebec, Canada).
27-Hydoxycholesterol-d5, 24-hydroxycholesterol and 24-hydroxycholesterol-d7
were purchased from Medical Isotopes (Pelham, AL, USA). Deuterated
standards obtained were of 495% purity.
Lanosterol, cholesterol and PC were dissolved in chloroform/methanol (1 : 1).
Cholesterol or lanosterol was mixed in equimolar proportion with PC and dried by
vacuum in a Speedvac (Thermosavant, Waltham, MA, USA). The lanosterol/PC or
cholesterol/PC mixture was resuspended in culture medium on the day of treatment
to make a 0.5 mM stock liposome. Each type of stock liposome was used in the
neuronal cultures within a day of preparation.
Lipid extraction. For tissues and cells, extraction of lipids was performed using
Bligh and Dyer method.39 Briefly, cells were washed 3–5 times with phosphate-
buffered saline (PBS), scraped in 400ml ice-cold methanol and transferred to a
1.5-ml Eppendorf tube. Chloroform (200ml) was added and samples were vortex for
1 min. Next, 300ml of 1 M KCL was added, and the homogenates were
microcentrifuged at 14 000 r.p.m. for 5 min at 4 1C to separate phases. The lower
organic phase was carefully transferred to a new Eppendorf tube. The aqueous
phase was re-extracted twice with 300ml chloroform. All organic phases were
pooled and dried under vacuum using a Speedvac and stored at 80 1C until
derivatization and subsequent GC–MS analysis.
Ventral midbrain (B20–25 mg) and striatum (B15–20 mg) were dissected and
tissues were homogenized using a Dounce homogenizer in 600ml ice-cold
chloroform/methanol (1 : 2). Another 300ml chloroform was added to the
homogenate followed by the addition of 450ml of 1 M KCL. The homogenates
were microcentrifuged at 14 000 r.p.m. for 5 min at 4 1C. The lower organic phase
was carefully transferred to a new Eppendorf tube, and the aqueous phase was re-
extracted twice with 300 ml chloroform. All organic phases were pooled and dried
under vacuum in a Speedvac. Dried samples were then stored at 80 1C until
derivatization and subsequent analyses.
Sample preparation for GC–MS. Briefly, dried lipid extracts were
resuspended in chloroform/methanol (1 : 1) to a concentration of 0.1 mg tissue/ml
solvent. A 20-ml sample of lipid extract was removed and completely dried in a glass
vial. For each sample, we added a mixture of heavy isotopes: 40 ng of
7a-hydroxycholesterol-d7, 40 ng of 7b-hydroxycholesterol-d7, 40 ng of 26(27)-
hydroxycholesterol-d5, 80 ng of 7-ketocholesterol-d7, 0.2mg of 5a-cholestane,
0.2mg of desmosterol-d6, 0.2mg of lathosterol-d4, 0.2mg of campesterol-d7 and
0.2mg of b-sitosterol-d7 in 25ml of ethanol. Standards and sample mixtures were
dried under a stream of N2 before adding the derivatizing agent (15 ml acetonitrile
and 15ml BSTFA þ TMCS; Pierce Thermoscientific, Waltham, MA, USA). The
derivatized samples were analyzed with an Agilent 5975 inert XL mass selective
detector (Santa Clara, CA, USA). Selective ion monitoring was performed using the
electron ionization mode at 70 eV (with the ion source maintained at 230 1C and the
quadrupole at 150 1C) to monitor one target ion. Two qualifier ions were selected for
the mass spectrum of each compound to optimize for sensitivity and specificity.
Ventral midbrain cultures. Ventral midbrains from 20 postnatal day 0 to day
2 rodents were dissected and digested in papain solution and plated on a glia layer.
Cells were cultured in serum-free neurobasal/B27 medium (Invitrogen, Carlsbad,
CA, USA) supplemented with superoxide dismutase 1 (5mg/ml), apo-transferrin
(95mg/ml) and insulin (21mg/ml) (all from Sigma). In contrast to Rayport et al.,40 our
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culture medium contained no serum because the cultures were subjected to lipid
addition in experimental conditions. One hour after plating the cells, 10 ng/ml of glial-
derived neurotrophic factor (Millipore, Billerica, MA, USA) was added. To inhibit glia
growth, a solution of 16.5 mg/ml uridine and 6.7 mg/ml 5-fluorodeoxyuridine was
added 1 day after plating. Cells were then cultured for 7 days (days in vitro (DIV)7)
before treatment with MPPþ and various types of liposome.
Hippocampal neuron cultures. Hippocampal neurons from rats E18.5
embryos were cultured in neurobasal/B27 as described.19 Briefly, neurons were
plated on a wax-dotted coverslip coated with 1 mg/ml of poly-D-lysine (Sigma). Two
hours after plating, when neurons had attached, the coverslips were flipped into a
six-well plate containing a glia feeder layer. PC, cholesterol or lanosterol liposome
(5mm each) was added after DIV7.
Western and antibodies. For western blots, cultured cells were washed
three times with 1 PBS. Cells were lysed in 100ml of RIPA buffer (50 mM Tris-
HCl, pH 7.4, 1% NP-40, 0.25% Na-deoxycholate, 150 mM NaCl and 1 mM EDTA),
supplemented with a cocktail of protease inhibitors (Complete Mini-EDTA inhibitors,
Roche Diagnostics, Indianapolis, IN, USA). In all, 20mg of cell protein lysate was
loaded in each well of a 10% polyacrylamide gel containing 0.1% SDS. After
electrophoresis, proteins were transferred to nitrocellulose membrane and probed
with the following antibodies: (i) rabbit anti-p35 (C19; 1 : 1000, Santa Cruz
Biotechnology, Santa Cruz, CA, USA), (ii) rabbit anti-LSS (1 : 1000, AVIA, Systems
Biology, San Diego, CA, USA), (iii) rabbit anti-tyrosine hydroxylase (TH) (1 : 20 000,
Covance, Princeton, NJ, USA), (iv) rabbit anti-SREBP2 (1 : 1000, Abcam,
Cambridge, MA, USA), (v) rabbit anti-calnexin (1 : 2000, Abcam), (vi) rabbit anti-
VDAC/porin (1 : 2000, Abcam) and (vii) rabbit anti-pGSK-3a/b (ser21/9) 1 : 1000,
Cell Signaling, Danvers, MA, USA). Peroxidase-conjugated anti-rabbit or anti-
mouse secondary antibodies (1 : 10 000) were purchased from Bio-Rad (Hercules,
CA, USA). Immunoblots were visualized with enhance chemiluminescence reagent
from Pierce Thermoscientific.
Fluorescence microscopy and quantification of dopaminergic
neuronal survival. Ventral midbrain cultures plated on 12-mm coverslips were
treated for 24 h with 10mM MPPþ with or without 5 mM PC, 5mM cholesterol or
5mM lanosterol liposome. Cells were washed three times with PBS, then fixed with
4% paraformaldehyde for 20 min, followed by permeabilization and blocking in 5%
fetal bovine serum in 0.1% TritonX-100 for 30 min. Cells were then stained with anti-
TH (secondary: Alexa-fluor 488, green) and neuron-specific class III beta tubulin
(TUJ1) (secondary: Alexa-fluor 555, red). Anti-mouse and anti-rabbit Alexa-fluor 488
and 555 (1 : 1000) were purchase from Molecular Probes (Eugene, OR, USA)/
Invitrogen. TUJ1-positive and TH-positive cells were counted with an Olympus
fluorescence microscope (Tokyo, Japan) with FITC and TRITC filter sets. Every
neuron on the 12-mm coverslip was counted. The percentage of dopaminergic
neurons in each group was determined by the number of THþ /TUJ1þ cells.
Typically, in each control coverslip, there were 2000–3000 TUJ1þ cells, of which
400–1200 were THþ . For each treatment, we assessed 4–6 coverslips per
independent experiment. The averages of 4–5 independent experiments are shown
in the figures.
Confocal microscopy and colocalization studies. Ventral midbrain
cultures in control and MPPþ -treated cells were stained with rabbit anti-LSS
(1 : 100), monoclonal mouse anti-TOMM20 (1 : 500) (Abcam) or monoclonal mouse
anti-KDEL (1 : 500) (Abcam), and sheep anti-TH (1 : 500) (Abcam). The secondary
antibodies, goat anti-mouse Alexa-fluor 555, goat anti-rabbit Alexa-fluor 488 and
donkey anti-sheep Alexa-fluor 633, were obtained from Invitrogen. Cells were
imaged with a laser-scanning confocal microscope (LSM510, Carl Zeiss,
Oberkochen, Germany) with excitation and emission filters meeting the
secondary Alexa-fluor antibody dye specifications. Images were taken using a
63X objective. To quantify colocalization, we plotted the pixel intensities of LSS
versus KDEL or TOMM20 from regions of interest (ROIs) drawn around single
neurons (either TH-positive or -negative), and calculated the linear regression
coefficient, R2, for 16–22 individual ROI/neuron.
Live-cell confocal imaging and measurement of mitochondrial
membrane potential. Mitochondrial membrane potential was measured in
live neurons using JC-1. All live-imaging experiments were conducted in cell
medium, (37 1C and 5% CO2) with a spinning disk confocal microscope, equipped
with a Cool SNAP HQ2 CCD camera (Photometrics, Tucson, AZ, USA), a fully
automated stage and built in autofocusing system (PFS, Nikon, Tokyo, Japan) and
driven by Metamorph 7.6 (Universal Imaging, Ypsilanti, MI, USA). JC-1 is excited at
488-nm, and its fluorescence emission was collected at 530±10 nm (green) and
590±17 nm (red), corresponding to peak fluorescence from the monomer and
aggregate signals, respectively. Mitochondrial membrane potential was measured
by taking the red to green emission ratio.
For ventral midbrain cultures (DIV7), cells were seeded at 50 cells/mm2 in a
glass-bottom labtek well. Cells were loaded with 1mg/ml JC-1 (Invitrogen) in culture
medium, and were incubated for 30 min at 37 1C, washed twice with HBSS and
imaged in conditioned culture medium. Multi-position time-lapse imaging of 10–15
randomly chosen fields was performed at 2-min interval over 40 min. At the end of
the experiment, ventral midbrain cells were fixed on stage for 20 min with 4% PFA
and stained for TH with a secondary antibody coupled to Alexafluro-568 (red) and
DAPI. The retrospective staining of TH allowed for the identification of dopaminergic
neurons, which were the only ones included in the analyses. Hippocampal cultures
were plated at a higher density (300 cells/mm2), and multi-position time-lapse
imaging of 3–4 fields was performed at 30-s intervals for 20 min.
For both types of cultures, the intensity of the JC-1 red-to-green ratio was
measured in each frame, and the change in mitochondrial membrane potential was
plotted as Df/f0, where f0 is the average JC-1 red-to-green ratio over the first 10
frames before treatment. Decay curves were fitted to a mono-exponential function,
y¼ x0et/t, using IGOR Pro 6.1 (WaveMetrics Inc., Lake Oswego, OR, USA).
Measurement of CoQ. For each condition, 3 to 4 million hippocampal
neurons (DIV7) were treated with various lipids and incubated for 24 h. Cells were
washed two times with cold PBS and scraped in 0.5 ml of cold PBS. Cells were
centrifuged at 1000 g to pellet the cells, and resuspended in 100ml fresh PBS.
Next, 750ml of hexane/ethanol (5 : 2 v/v) was added, and samples were vigorously
vortexed for 1 min. To extract CoQ, 400ml of the organic phase was collected and
completely dried under a stream of N2, followed by LC–MS analysis.
An Agilent HPLC 1200 system coupled with an Applied Biosystems 3200 QTrap
mass spectrometer (Foster City, CA, USA) was used for measuring CoQ8, Q9, and
Q10 and free cholesterol. Chromatographic separation was carried out using an
Agilent Zorbax Eclipse XDB-C18 column (i.d. 4.6 150 mm). High-pressure liquid
chromatography (HPLC) conditions were as the following: mobile phase:
chloroform/methanol 1 : 1 (v/v); flow rate: 0.5 ml/min; column temperature: 30 1C;
injection volume: 10ml. The LC–MS instrument was operated in positive
atmospheric pressure chemical ionization mode with a vaporizer temperature of
500 1C and a corona current of 3 mA. CoQ6 was used as an internal standard and
monitored with an multiple reaction monitoring (MRM) transition of 591.4197.0.
MRM transitions of 727.5197.0, 795.5197.0 and 863.6197.0 were set up for analysis
of CoQ8, Q9 and Q10, respectively.
Quantification of AVs. Ventral midbrain cultures plated on 12-mm coverslips
were treated for 24 h with 10mM MPPþ with or without 5 mM PC, 5mM cholesterol
or 5 mM lanosterol. Cells were washed three times with PBS, then fixed with 4%
paraformaldehyde for 20 min and permeabilized with 100mg/ml of digitonin for
10 min. Following permeabilization, cells were washed three times with PBS and
stained with anti-TH (secondary: Alexa-fluor 488, green) and anti-LC3 (1 : 100,
mouse monoclonal, MBL cat. no.: 152–3A, secondary: Alexa-fluor 555, red). To
quantify AV in dopaminergic neurons, THþ cell soma were imaged with a laser-
scanning confocal microscope (LSM510, Carl Zeiss) with excitation and emission
filters meeting the secondary Alexa-fluor antibody dye specifications. Images were
taken using a 63X objective with the same laser power and gain. The 12-bit images
were quantified using ImageJ (analyze particle drop-in, National Institute of Health,
Bethesda, MD, USA). For each image, detected LC3 puncta were intensity thresholded
(o1000) and gated for size (o15 pixel). For each condition, 40–60 THþ cells were
assessed from three independent experiments.
As a positive control for our method of evaluating AV, mouse embryonic
fibroblast grown in serum or serum deprived were stained with LC3 and quantified
according to the same parameters. As expected and shown in supplementary data
(Supplementary Figure S2), there is approximately a 25-fold increase in AV on
serum starvation.
Quantification of mitophagy in axons. E18.5 hippocampal neurons
were electroporated using the Amaxa poration system (Lonza, Basel, Switzerland)
with MitoRed construct (Clonetech, Mountain View, CA, USA, cat. No.: PT-3633-5).
Cells were then plated in microfluidic chambers (Xona Microfluidics, Temecula, CA,
USA), which allow for physical separation of axons and cell somas. At DIV7,
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neurons were treated with 5 mM PC, 5mM cholesterol, 5 mM lanosterol or 200 nM of
rapamycin (positive control) for 24 h. Cells were then fixed with 4%
paraformaldehyde for 20 min and permeabilized with 100mg/ml of digitonin for
10 min. Following permeabilization, cells were washed three times with PBS, and
stained with anti-LC3 (secondary: Alexa-fluor 488, green). To quantify mitophagy,
the percentage of MitoRed and LC3-positive mitochondria were plotted as a
percentage to total MitoRed-positive mitochondria using the Metamorph 7.6
colocalization drop-in. For each condition, images of 40–50 axons were taken from
three independent experiments.
Statistical analyses. Error bars represent S.E.M. For fold changes in sterol
intermediates, P-values were calculated with two-tailed Mann–Whitney U-test. For
in vitro assessment of dopaminergic neuron survival, CoQ levels, ATP levels, AV
number and size, percentage of mitophagy, P-values were calculated with
two-tailed Student’s t-test.
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